ABLD Stock Overview
Provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ABL Diagnostics Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.50 |
| 52 Week High | €3.18 |
| 52 Week Low | €2.50 |
| Beta | -0.22 |
| 1 Month Change | -12.59% |
| 3 Month Change | -10.71% |
| 1 Year Change | -74.23% |
| 3 Year Change | -13.04% |
| 5 Year Change | -36.71% |
| Change since IPO | 132.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABLD | FR Trade Distributors | FR Market | |
|---|---|---|---|
| 7D | -0.8% | -3.2% | -1.7% |
| 1Y | -74.2% | -6.9% | -4.8% |
Return vs Industry: ABLD underperformed the French Trade Distributors industry which returned -6.9% over the past year.
Return vs Market: ABLD underperformed the French Market which returned -4.8% over the past year.
Price Volatility
| ABLD volatility | |
|---|---|
| ABLD Average Weekly Movement | 3.1% |
| Trade Distributors Industry Average Movement | 3.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ABLD has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ABLD's weekly volatility has decreased from 10% to 3% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 17 | Chalom Sayada | www.abldiagnostics.com |
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation system, and sanger sequencing reagents. The company also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB.
ABL Diagnostics Société anonyme Fundamentals Summary
| ABLD fundamental statistics | |
|---|---|
| Market cap | €40.28m |
| Earnings (TTM) | €184.66k |
| Revenue (TTM) | €6.21m |
218.2x
P/E Ratio6.5x
P/S RatioIs ABLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABLD income statement (TTM) | |
|---|---|
| Revenue | €6.21m |
| Cost of Revenue | €4.73m |
| Gross Profit | €1.48m |
| Other Expenses | €1.30m |
| Earnings | €184.66k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.011 |
| Gross Margin | 23.89% |
| Net Profit Margin | 2.97% |
| Debt/Equity Ratio | 45.1% |
How did ABLD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:18 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ABL Diagnostics Société anonyme is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jean-Pierre Loza | In Extenso Financement & Marché |